Psychedelics startup nets more than $10M in seed funding as it looks to make a splash
As companies small and large begin to test the waters and go mainstream with a series of different psychedelics, one startup is hoping to use an expert in the field to advance a therapy using ketamine for major depressive disorder.
Freedom Biosciences, a clinical-stage company developing therapeutics using ketamine and other psychedelics, has netted itself $10.5 million in seed financing.
The company was founded last April by John Krystal, the chair of the Department of Psychiatry at Yale University, and Dina Burkitbayeva, co-founder of PsyMed Ventures. Burkitbayeva now serves as the startup’s CEO, while Krystal serves as chief scientific advisor.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters